secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001628280-26-011395
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River to divest CDMO/Cell Solutions and European Discovery assets; updates 2026 guidance
--------------------------------------------------------------------------------

- Definitive agreement to sell CDMO and Cell Solutions to GI Partners for future performance-based payments; $143M 2025 revenue.
- Agreement to sell certain European Discovery Services assets to IQVIA for ~$145M cash plus up to $10M contingent; $144M 2025 revenue.
- Updated 2026 guidance: reported revenue growth (5.0)% to (3.5)%; non-GAAP EPS $10.80-$11.30.
- Divestitures expected to reduce 2026 reported revenue by >$200M, but add at least 100 bps non-GAAP operating margin and ~$0.10 EPS.
- Both transactions expected to close in Q2 2026, subject to customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000162828026011395/0001628280-26-011395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000162828026011395/crl-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-011395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer